Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00191074 · ClinicalTrials.gov registry record · Phase 3
Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 11
- Enrollment target
NCT00191074 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 11 participants.
The verdict
NCT00191074, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 11 participants
- Enrollment target
Study Summary
After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted. All of these patients were offered the opportunity to enter the unblinded extension phase (if they met eligibility criteria) and continue somatropin treatment (regardless of initial treatment randomization) until they reached final height.
Interventions
- DRUG somatropin, rDNA origin, for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2001-02 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00191074
The ClinicalTrials.gov registry entry for NCT00191074 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which somatropin, rDNA origin, for injection is the first listed.
NCT00191074 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00191074 about?
NCT00191074 is a clinical study titled "Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature". After approval of amendment (g), patients who were still receiving study drug at the time were scheduled for a study visit. In addition, patients who had discontinued early from the core, blinded phase of the study were contacted. All of these patients were offered the opportunity to enter the unbl...
What is the current status of trial NCT00191074?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 11 participants. The study started on 2001-02. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00191074?
The interventions under investigation include: somatropin, rDNA origin, for injection (DRUG).
Who is sponsoring clinical trial NCT00191074?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.